Actively Recruiting
Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics
Led by Milton S. Hershey Medical Center · Updated on 2026-02-12
800
Participants Needed
13
Research Sites
128 weeks
Total Duration
On this page
Sponsors
M
Milton S. Hershey Medical Center
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the management AP as well as potentially extending the licensing authorization for CGM to include use in patients with pancreatogenic (Type 3c) DM.
CONDITIONS
Official Title
Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of acute pancreatitis (AP) within 0 to 90 days before enrollment
- Ability to fully understand and participate in all study procedures including informed consent, case report forms, telephone interviews, metabolic testing, and follow-ups
You will not qualify if you...
- Definite chronic pancreatitis at enrollment based on CT, MRI, or MRCP showing calcifications or ductal defects
- Hospitalization less than 48 hours for post-ERCP acute pancreatitis
- Previous endoscopic or percutaneous necrosectomy or drainage before enrollment
- Presence of pancreatic tumors including ductal adenocarcinoma or neuroendocrine tumors
- Confirmed or suspected cystic tumor causing AP
- Prior pancreatic surgeries such as distal pancreatectomy or pancreaticoduodenectomy
- Use of disallowed medications within 30 days before enrollment
- Severe systemic illnesses including history of organ transplant, AIDS, recent cancer treatment, advanced kidney disease, or decompensated cirrhosis
- Known pregnancy at enrollment
- Incarceration
- Any condition compromising safety or study integrity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
University of Southern California
Los Angeles, California, United States, 90033
Actively Recruiting
2
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Actively Recruiting
3
Stanford University
Stanford, California, United States, 94305
Actively Recruiting
4
University of Florida
Gainesville, Florida, United States, 32610-0214
Actively Recruiting
5
AdventHealth
Orlando, Florida, United States, 32804
Actively Recruiting
6
Northwestern University
Chicago, Illinois, United States, 60611
Actively Recruiting
7
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Actively Recruiting
8
Indiana University
Indianapolis, Indiana, United States, 46202
Actively Recruiting
9
Johns Hopkins University
Baltimore, Maryland, United States, 21205
Actively Recruiting
10
University of Minnesota
Minneapolis, Minnesota, United States, 55454
Actively Recruiting
11
Ohio State University
Columbus, Ohio, United States, 43210
Actively Recruiting
12
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
13
Benaroya Research Institute
Seattle, Washington, United States, 98101
Actively Recruiting
Research Team
R
Ron Zimmerman, MPA
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here